Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.
Guided Therapeutics Price Performance
GTHP opened at $0.11 on Tuesday. The company’s 50-day moving average is $0.18 and its 200 day moving average is $0.24. Guided Therapeutics has a fifty-two week low of $0.10 and a fifty-two week high of $0.54. The firm has a market capitalization of $10.80 million, a P/E ratio of -2.75 and a beta of 0.78.
Guided Therapeutics Company Profile
Guided Therapeutics is a medical technology company focused on developing tools for the detection of cervical disease. Its principal product is the LuViva Advanced Cervical Scan, a non-invasive device designed to assess cervical tissue for signs associated with precancerous changes and cancer. LuViva uses optical technologies to examine tissue and provide information that can support cervical disease evaluation. The company’s work centers on offering an alternative to diagnostic approaches that rely on collecting and analyzing tissue samples.
Read More
- Five stocks we like better than Guided Therapeutics
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
